LEGN Q2 2026: CARVYKTI Sales Surge 50% Amid In Vivo CAR-T Clinical Breakthroughs
Legend Biotech’s second quarter showcased robust global demand for CARVYKTI alongside pioneering clinical proof-of-concept for its in vivo CAR-T platform, underpinning a strategic pivot toward diversified cell therapies. The company’s strengthened financial position and operational leverage support sustained investment in innovation and global expansion. Forward momentum is anchored on advancing pipeline milestones and maintaining profitability through 2026.
Summary
- Global Commercial Expansion: Rapid CARVYKTI adoption drives broad market penetration and earlier line therapy utilization.
- Innovation Milestone: First-in-human data validate in vivo CAR-T platform with promising safety and efficacy profiles.
- Financial Discipline: Strengthened balance sheet and adjusted net income profitability underpin growth and R&D investment.
Business Overview
Legend Biotech is a leading cell therapy company specializing in chimeric antigen receptor T-cell (CAR-T) therapies primarily targeting hematologic malignancies. The company generates revenue through collaboration agreements, notably with Johnson & Johnson (J&J), commercializing CARVYKTI, a CAR-T therapy for multiple myeloma, and advancing a diversified pipeline including autologous, allogeneic, and in vivo CAR-T modalities. Key business segments include product sales, collaboration revenue, and license income derived from milestone achievements and partnerships.
Performance Analysis
In Q2 2026, Legend Biotech achieved a 50% year-over-year increase in CARVYKTI net trade sales, reaching approximately $657 million. U.S. sales grew 32% while ex-U.S. markets surged 128%, reflecting both deepening market penetration and geographic expansion to 19 global markets with 348 authorized treatment sites. Sequential growth was strong globally, with a 10% increase over Q1 driven by accelerating adoption in earlier lines of therapy, now comprising over 70% of volume in the U.S., and a growing outpatient treatment mix approaching 60%.
The company reported adjusted net income of $63 million, marking a milestone as Legend Biotech’s first quarter of company-wide profitability on both IFRS and adjusted bases. Operating margins improved to 15% from negative 9% year-over-year, supported by higher gross margins on net product sales, which increased to 58% from 41% in Q1, aided by the unwinding of one-time manufacturing costs. Total operating expenses grew modestly by 7%, reflecting disciplined investment aligned with scaling commercial operations and pipeline advancement.
- Revenue Diversification: Collaboration and license revenues increased significantly due to CARVYKTI sales and milestone achievements under the Janssen Agreement.
- Cost Efficiency: Research and development expenses declined 2% as late-stage clinical trial dosing phases concluded, offset by increased investment in in vivo CAR-T programs.
- Tax Expense Dynamics: Income tax expense rose substantially due to higher taxable income and the reflection of a provisional advanced pricing agreement with Chinese tax authorities.
Legend’s financial performance underscores the scalability of its business model, balancing growth and profitability while investing in next-generation cell therapies. The cash position of approximately $965 million provides flexibility to fund pipeline development and manufacturing expansion.
Executive Commentary
"Our second quarter results demonstrate the strength of our commercial and innovation engines at Legend Biotech. CARVYKTI continued to deliver growth as we expand patient access globally, including the most recent launch in Ireland, our 19th market. Commercial momentum of CARVYKTI provides the foundation to advance a diversified portfolio of next-generation cell therapies designed to expand the reach and impact of CAR-T."
Alan Bash, Interim Chief Executive Officer
"This quarter's financial results continue to demonstrate the operating leverage inherent in our business model. Revenue has scaled at a CAGR of 74% since Q2 2023, supported by growing demand for CARVYKTI and continued commercial execution. Operating margins improved significantly, marking a major milestone as the first quarter of company-wide profitability on both IFRS and an adjusted basis."
Carlos Santos, Chief Financial Officer
Strategic Positioning
1. Expanding CARVYKTI’s Global Footprint and Earlier Line Penetration
Legend Biotech continues to prioritize broadening CARVYKTI’s availability, recently launching in Ireland and growing the activated treatment site network to 348 globally. The strategic emphasis on increasing usage in second to fourth lines of therapy, now over 70% of U.S. volume, reflects a deliberate effort to capture earlier treatment settings, which typically offer better patient outcomes and commercial durability. The growing outpatient treatment mix indicates a shift toward more accessible administration settings, although this introduces new gross margin dynamics.
2. Pioneering In Vivo CAR-T Platform with Clinical Proof-of-Concept
The company achieved a significant innovation milestone with LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. Early Phase 1 data demonstrated a 100% objective response rate and 83.3% complete response rate at the higher dose level, with durable in vivo CAR-T persistence and a favorable safety profile. This platform offers broad applicability across hematologic malignancies and solid tumors, representing a potential paradigm shift in CAR-T therapy delivery by enabling direct in vivo cell modification without lymphodepletion.
3. Financial Strength Enables Accelerated Pipeline Investment
Following a successful $212 million equity offering, Legend Biotech’s cash and equivalents stand at $965 million, providing a robust financial runway beyond 2026. This capital strength supports accelerated development of in vivo candidates, including the upcoming IND filing for LB2501 in the U.S., and modest capital expenditures for manufacturing capacity expansion. The company’s disciplined approach balances growth investments with sustained adjusted net income profitability.
4. Collaboration Model and Revenue Growth from Janssen Partnership
Collaboration revenue increased substantially due to CARVYKTI sales and milestone payments under the Janssen Agreement. Legend’s profit split model and revenue recognition practices reflect increasing international sales, with foreign exchange considerations becoming more pronounced as ex-U.S. sales grow. The collaboration remains central to Legend’s commercial success and pipeline advancement, particularly for BCMA-targeted therapies.
5. Leadership Continuity Amid Executive Transition
The appointment of Alan Bash as interim CEO signals a leadership transition focused on continuity rather than strategic shifts. Management emphasizes maintaining momentum in CARVYKTI commercialization, advancing the next-generation pipeline, and delivering operational discipline. The board’s ongoing search for a permanent CEO reflects a holistic approach to leadership selection aligned with the company’s growth stage and innovation ambitions.
Key Considerations
Legend Biotech’s Q2 2026 results highlight a company at a strategic inflection point, balancing commercial scale with innovation leadership in cell therapy.
- Commercial Execution: Sustained growth in CARVYKTI sales, especially in earlier lines and international markets, underpins revenue momentum and market leadership in multiple myeloma CAR-T therapy.
- Pipeline Diversification: The in vivo CAR-T platform’s promising early data validate a novel approach that could expand Legend’s addressable market beyond hematologic cancers into solid tumors and autoimmune diseases.
- Operational Leverage: Margin expansion and controlled expense growth demonstrate effective scaling, though gross margin variability is expected due to outpatient mix and manufacturing dynamics.
- Financial Flexibility: A strong cash position and debt reduction enhance the company’s ability to accelerate R&D and manufacturing investments without compromising profitability goals.
- Regulatory and Tax Complexity: The provisional advanced pricing agreement with Chinese tax authorities introduces new tax expense considerations and potential cash flow impacts, requiring careful modeling.
Risks
Risks include potential variability in gross margins driven by shifts to outpatient treatment settings and international market dynamics. The advanced pricing agreement with Chinese tax authorities, while providing some certainty, may lead to materially different tax liabilities. Clinical and regulatory risks remain inherent to the early-stage in vivo CAR-T programs, and competition from bispecific antibodies and other CAR-T therapies could impact market share and pricing power. Leadership transition introduces execution risk, though management emphasizes continuity.
Forward Outlook
For Q3 and Q4 2026, Legend Biotech expects continued sequential global sales growth, supported by further international expansion and an additional selling week in Q4. Gross margin on net product sales is anticipated to fluctuate, with Q3 expected in the lower 50% range and a rebound to mid-50% in Q4. The company maintains guidance for adjusted net income profitability for the second half of 2026. Key milestones include filing a U.S. IND for LB2501 by year-end and presenting additional in vivo CAR-T clinical data at upcoming medical conferences.
Takeaways
Legend Biotech’s Q2 results underscore a commercial and innovation engine firing on multiple cylinders, positioning the company for durable growth and leadership in cell therapy.
- Commercial Momentum: CARVYKTI’s 50% sales growth and penetration into earlier lines validate the company’s strategy to expand market reach and patient access globally.
- Innovation Validation: The LB2501 in vivo CAR-T clinical proof-of-concept marks a potential breakthrough, signaling a new modality that could reshape CAR-T therapy development and delivery.
- Financial Discipline and Flexibility: Achieving adjusted net income profitability and bolstering cash reserves through equity raises provide a foundation to invest aggressively in pipeline advancement while managing operational leverage.
Conclusion
Legend Biotech’s Q2 2026 performance reflects a company successfully scaling its flagship CARVYKTI product while breaking new ground with its in vivo CAR-T platform. The combination of robust commercial execution, innovation milestones, and financial strength positions Legend for sustained growth and leadership in the evolving cell therapy landscape.
Industry Read-Through
Legend Biotech’s progress highlights the increasing commercialization maturity of CAR-T therapies alongside the emergence of next-generation modalities such as in vivo CAR-T. The company’s ability to expand patient access globally and penetrate earlier treatment lines illustrates a broader industry trend toward optimizing CAR-T positioning within oncology treatment paradigms. Additionally, the promising in vivo CAR-T data may accelerate industry interest in gene-modification approaches that bypass ex vivo manufacturing, potentially reducing costs and expanding indications. Investors and competitors should monitor Legend’s pipeline developments and commercial strategies as indicators of evolving market dynamics and innovation trajectories in cell therapy.